News

India's MedPlus Health posts two-fold surge in Q4 profit on strong sales India's MedPlus Health Services reported a two-fold surge in fourth-quarter profit on Thursday, driven by strong sales in its key retail segment. The omnichannel retail pharmacy said its consolidated net profit rose to 265.8 million rupees ($3.21 million) for the quarter ended March 31, from 117.3 million rupees a year ago. The company's consolidated revenue from operations rose 30%, thriving on the back of improved accessibility among consumers - the company sells medicines onl...
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
India's MedPlus Health posts two-fold surge in Q4 profit on strong sales
Source: Reuters
26/05/2023 9:00:35 AM
Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara Alembic Pharmaceuticals is currently trading at Rs. 574.85, up by 3.10 points or 0.54% from its previous closing of Rs. 571.75 on the BSE. The scrip opened at Rs. 573.85 and has touched a high and low of Rs. 582.85 and Rs. 563.65 respectively. So far 3516 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 775.00 on 24-May-2022 and a 52 week low of Rs. 463.30 on 29-Mar-2023. Last one week high and low of the scrip s...
Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara
Alembic Pharmaceuticals surges on getting EIR for Solid Oral Formulation Facility at Vadodara
Source: Accord Fintech
10/05/2023 3:39:11 PM
Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations Alembic Pharmaceuticals is currently trading at Rs. 486.70, up by 2.25 points or 0.46% from its previous closing of Rs. 484.45 on the BSE. The scrip opened at Rs. 483.10 and has touched a high and low of Rs. 490.00 and Rs. 479.35 respectively. So far 1534 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 792.30 on 28-Apr-2022 and a 52 week low of Rs. 475.00 on 17-Mar-2023. Last one week high and low of the scrip s...
Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations
Alembic Pharmaceuticals gains on completing ANVISA GMP audit at API-III Facility without any observations
Source: Accord Fintech
27/03/2023 12:05:48 PM
Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations Alembic Pharmaceuticals is currently trading at Rs. 490.50, up by 3.20 points or 0.66% from its previous closing of Rs. 487.30 on the BSE. The scrip opened at Rs. 496.55 and has touched a high and low of Rs. 496.55 and Rs. 484.65 respectively. So far 2454 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 792.30 on 28-Apr-2022 and a 52 week low of Rs. 476.30 on 03-Mar-2023. Last one week high and low of the scrip s...
Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations
Alembic Pharmaceuticals trades higher on completing USFDA`s inspection at Derma Facility without any observations
Source: Accord Fintech
14/03/2023 12:23:54 PM
Buy Alembic Pharma Ltd For Target Rs. 680 - Yes Securities US inflection unlikely soon; ADD retained Result Synopsis Alembic Pharma managed to report a steady quarter as fear of a reversal in US on back of one-off opportunity in Q2 did not materialize. India continued with its healthy run and clocked ~11.5% growth YoY. OPM maintained their recovery from Q2 and included ~50bps worth of Aleor R&D write-off which is nearing its guided end. Management reiterated Rs2bn of operating cost hit to expenses as onco and general injectable plants come ...
Buy Alembic Pharma Ltd For Target Rs. 680 - Yes Securities
Buy Alembic Pharma Ltd For Target Rs. 680 - Yes Securities
Source: Yes Securities Ltd
13/03/2023 12:08:23 PM
Key Stock Ideas: Alembic Pharma, Byju`s, Bessemer India Capital, Power Grid Corporation - ARETE Securities Alembic Pharma gets USFDA nod to market generic antidepressant drug: Alembic Pharmaceuticals on Thursday said it has received an approval from the US health regulator to market a generic antidepressant medication in the American market. The company has received an approval from the US Food & Drug Administration to market Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg, the drug firm said in a statement. The company's product is therapeutically equiv...
Key Stock Ideas: Alembic Pharma, Byju`s, Bessemer India Capital, Power Grid Corporation - ARETE Securities
Key Stock Ideas: Alembic Pharma, Byju`s, Bessemer India Capital, Power Grid Corporation - ARETE Securities
Source: Axis Securities Ltd
10/03/2023 9:29:29 AM
Alembic Pharmaceuticals rises on getting USFDA`s tentative approval for Brexpiprazole Tablets Alembic Pharmaceuticals is currently trading at Rs. 519.05, up by 6.75 points or 1.32% from its previous closing of Rs. 512.30 on the BSE. The scrip opened at Rs. 512.55 and has touched a high and low of Rs. 519.05 and Rs. 512.55 respectively. So far 331 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 792.30 on 28-Apr-2022 and a 52 week low of Rs. 476.30 on 03-Mar-2023. Last one week high and low of the scrip st...
Alembic Pharmaceuticals rises on getting USFDA`s tentative approval for Brexpiprazole Tablets
Alembic Pharmaceuticals rises on getting USFDA`s tentative approval for Brexpiprazole Tablets
Source: Accord Fintech
9/03/2023 9:37:28 AM
Alembic Pharmaceuticals spurts on getting USFDA`s final approval for Fluorouracil Injection Alembic Pharmaceuticals is currently trading at Rs. 516.90, up by 15.35 points or 3.06% from its previous closing of Rs. 501.55 on the BSE. The scrip opened at Rs. 509.35 and has touched a high and low of Rs. 516.90 and Rs. 507.70 respectively. So far 1760 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 792.30 on 28-Apr-2022 and a 52 week low of Rs. 476.30 on 03-Mar-2023. Last one week high and low of the scrip ...
Alembic Pharmaceuticals spurts on getting USFDA`s final approval for Fluorouracil Injection
Alembic Pharmaceuticals spurts on getting USFDA`s final approval for Fluorouracil Injection
Source: Accord Fintech
6/03/2023 11:28:06 AM
Alembic Pharmaceuticals gains on getting nod for Fulvestrant Injection from USFDA Alembic Pharmaceuticals is currently trading at Rs. 587.10, up by 5.50 points or 0.95% from its previous closing of Rs. 581.60 on the BSE. The scrip opened at Rs. 572.05 and has touched a high and low of Rs. 592.65 and Rs. 572.05 respectively. So far 1034 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals gains on getting nod for Fulvestrant Injection from USFDA
Alembic Pharmaceuticals gains on getting nod for Fulvestrant Injection from USFDA
Source: Accord Fintech
26/12/2022 9:58:29 AM
Alembic Pharmaceuticals rises on receiving PAS approval from USFDA for Pregabalin Capsules Alembic Pharmaceuticals is currently trading at Rs. 589.85, up by 1.20 points or 0.20% from its previous closing of Rs. 588.65 on the BSE. The scrip opened at Rs. 586.60 and has touched a high and low of Rs. 600.00 and Rs. 584.10 respectively. So far 1917 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals rises on receiving PAS approval from USFDA for Pregabalin Capsules
Alembic Pharmaceuticals rises on receiving PAS approval from USFDA for Pregabalin Capsules
Source: Accord Fintech
23/12/2022 10:48:34 AM
Sell Alembic Pharmaceuticals Ltd For Target Rs.570 - Motilal Oswal Financial Services Strong execution drives earnings beat Enhanced effort required to improve return ratios; maintain SELL * Alembic Pharma (ALPM) delivered better-than-expected earnings for 2QYF23, fueled by healthy growth across domestic formulation (DF), exports as well as API segments. Part of the earnings was boosted by certain one-time opportunities in the US generics segment. * We raise our EPS estimate for FY23 by 5% to factor in: a) superior traction in the US generics segment, b) better-than-i...
Sell Alembic Pharmaceuticals Ltd For Target Rs.570 - Motilal Oswal Financial Services
Sell Alembic Pharmaceuticals Ltd For Target Rs.570 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
15/12/2022 2:50:56 PM
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Diclofenac Sodium Topical Solution Alembic Pharmaceuticals is currently trading at Rs. 597.95, up by 2.95 points or 0.50% from its previous closing of Rs. 595.00 on the BSE. The scrip opened at Rs. 593.00 and has touched a high and low of Rs. 606.50 and Rs. 593.00 respectively. So far 2940 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Diclofenac Sodium Topical Solution
Alembic Pharmaceuticals surges on getting USFDA`s final approval for Diclofenac Sodium Topical Solution
Source: Accord Fintech
1/12/2022 2:14:45 PM
Alembic Pharmaceuticals gains on getting USFDA`s nod for Nifedipine Extended-Release Tablets Alembic Pharmaceuticals is currently trading at Rs. 630.75, up by 5.40 points or 0.86% from its previous closing of Rs. 625.35 on the BSE. The scrip opened at Rs. 617.05 and has touched a high and low of Rs. 634.70 and Rs. 617.05 respectively. So far 755 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip st...
Alembic Pharmaceuticals gains on getting USFDA`s nod for Nifedipine Extended-Release Tablets
Alembic Pharmaceuticals gains on getting USFDA`s nod for Nifedipine Extended-Release Tablets
Source: Accord Fintech
21/11/2022 12:08:55 PM
Alembic Pharmaceuticals jumps on getting USFDA`s approval for Cyclophosphamide Capsules Alembic Pharmaceuticals is currently trading at Rs. 647.70, up by 8.40 points or 1.31% from its previous closing of Rs. 639.30 on the BSE. The scrip opened at Rs. 641.50 and has touched a high and low of Rs. 651.25 and Rs. 640.40 respectively. So far 3600 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals jumps on getting USFDA`s approval for Cyclophosphamide Capsules
Alembic Pharmaceuticals jumps on getting USFDA`s approval for Cyclophosphamide Capsules
Source: Accord Fintech
15/11/2022 12:43:54 PM
Alembic Pharmaceuticals zooms on getting final nod for Ketorolac Tromethamine Injection Alembic Pharmaceuticals is currently trading at Rs. 661.55, up by 49.35 points or 8.06% from its previous closing of Rs. 612.20 on the BSE. The scrip opened at Rs. 608.70 and has touched a high and low of Rs. 675.00 and Rs. 603.55 respectively. So far 143890 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scri...
Alembic Pharmaceuticals zooms on getting final nod for Ketorolac Tromethamine Injection
Alembic Pharmaceuticals zooms on getting final nod for Ketorolac Tromethamine Injection
Source: Accord Fintech
3/11/2022 12:40:46 PM
Rss Feed Alembic Pharmaceuticals moves up on getting final approval for Mesalamine Extended-Release Capsules from USFDA Alembic Pharmaceuticals is currently trading at Rs. 602.05, up by 23.60 points or 4.08% from its previous closing of Rs. 549.95 on the BSE. The scrip opened at Rs. 580.35 and has touched a high and low of Rs. 602.00 and Rs. 574.90 respectively. So far 14552 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip...
Rss Feed Alembic Pharmaceuticals moves up on getting final approval for Mesalamine Extended-Release Capsules from USFDA
Rss Feed Alembic Pharmaceuticals moves up on getting final approval for Mesalamine Extended-Release Capsules from USFDA
Source: Accord Fintech
2/11/2022 10:41:06 AM
Alembic Pharmaceuticals gains on getting USFDA`s approval for Glycopyrrolate Injection Alembic Pharmaceuticals is currently trading at Rs. 553.30, up by 3.35 points or 0.61% from its previous closing of Rs. 549.95 on the BSE. The scrip opened at Rs. 552.70 and has touched a high and low of Rs. 557.95 and Rs. 550.00 respectively. So far 3408 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals gains on getting USFDA`s approval for Glycopyrrolate Injection
Alembic Pharmaceuticals gains on getting USFDA`s approval for Glycopyrrolate Injection
Source: Accord Fintech
1/11/2022 2:36:29 PM
Alembic Pharmaceuticals gains on getting final nod for Paclitaxel Injection from USFDA Alembic Pharmaceuticals is currently trading at Rs. 549.20, up by 1.05 points or 0.19% from its previous closing of Rs. 548.15 on the BSE. The scrip opened at Rs. 551.25 and has touched a high and low of Rs. 552.35 and Rs. 542.50 respectively. So far 7803 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022. Last one week high and low of the scrip s...
Alembic Pharmaceuticals gains on getting final nod for Paclitaxel Injection from USFDA
Alembic Pharmaceuticals gains on getting final nod for Paclitaxel Injection from USFDA
Source: Accord Fintech
27/10/2022 4:14:08 PM
Buy Alembic Pharmaceuticals Ltd For Target Rs. 590 - Yes Securities Numbers dwindle; US traction key for margins, return ratios About the stock: Alembic Pharma operates in international generics (US:31% & exUS: 15% in FY22), domestic branded (36% in FY22) and API (18% in FY22). * Domestic business has 1.5% of market share of IPM with three brands in the top 300. Going ahead, emphasis is on the specialty segment * The company has invested ~ | 1800 crore in recent years in facilities geared mainly towards US formulations. As of Q1FY23, it has filed...
Buy Alembic Pharmaceuticals Ltd For Target Rs. 590 - Yes Securities
Buy Alembic Pharmaceuticals Ltd For Target Rs. 590 - Yes Securities
Source: ICICI Direct Ltd
5/10/2022 4:26:41 PM
Alembic Pharma rises on getting USFDA's final approval for Chlorthalidone Tablets Alembic Pharmaceuticals is currently trading at Rs. 656.00, up by 5.60 points or 0.86% from its previous closing of Rs. 650.40 on the BSE. The scrip opened at Rs. 644.35 and has touched a high and low of Rs. 662.15 and Rs. 642.85 respectively. So far 3159 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 863.10 on 12-Oct-2021 and a 52 week low of Rs. 641.80 on 23-Aug-2022. Last one week high and low of the scrip s...
Alembic Pharma rises on getting USFDA's final approval for Chlorthalidone Tablets
Alembic Pharma rises on getting USFDA's final approval for Chlorthalidone Tablets
Source: Accord Fintech
29/08/2022 2:17:32 PM
Buy Alembic Pharmaceuticals Ltd For Target Rs.830 - Yes Securities Margin pressure from US leads a D/G to ADD Result Synopsis Alembic Pharma reported an extremely weak set of numbers with US revenues down 34% QoQ and flat YoY. Even taking out Aleor write off Rs1.15bn, margin at ~10% was much below expectation. Importantly, company refused to provide some direction on gross margin, an indication of the volatility in US business (corroborated by Lupin’s US sales & others reporting so far) with price erosion being persistent in double digit in 1...
Buy Alembic Pharmaceuticals Ltd For Target Rs.830 - Yes Securities
Buy Alembic Pharmaceuticals Ltd For Target Rs.830 - Yes Securities
Source: Yes Securities Ltd
18/08/2022 5:49:10 PM
Alembic Pharma rises as its arm gets USFDA`s nod for Diclofenac Sodium Topical Gel Alembic Pharmaceuticals is currently trading at Rs. 701.80, up by 0.65 points or 0.09% from its previous closing of Rs. 701.15 on the BSE. The scrip opened at Rs. 701.20 and has touched a high and low of Rs. 707.50 and Rs. 695.25 respectively. So far 4792 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 863.10 on 12-Oct-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip s...
Alembic Pharma rises as its arm gets USFDA`s nod for Diclofenac Sodium Topical Gel
Alembic Pharma rises as its arm gets USFDA`s nod for Diclofenac Sodium Topical Gel
Source: Accord Fintech
29/07/2022 12:25:30 PM
Alembic Pharmaceuticals rises on getting USFDA tentative nod for Dasatinib tablets Alembic Pharmaceuticals is currently trading at Rs. 735.70, up by 3.60 points or 0.49% from its previous closing of Rs. 732.10 on the BSE. The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 740.90 and Rs. 728.90 respectively. So far 1704 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1025.00 on 11-Jun-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharmaceuticals rises on getting USFDA tentative nod for Dasatinib tablets
Alembic Pharmaceuticals rises on getting USFDA tentative nod for Dasatinib tablets
Source: Accord Fintech
10/06/2022 11:51:16 AM
Alembic Pharmaceuticals trades higher on getting final nod from USFDA for Pirfenidone Tablets Alembic Pharmaceuticals is currently trading at Rs. 767.75, up by 7.35 points or 0.97% from its previous closing of Rs. 760.40 on the BSE. The scrip opened at Rs. 760.70 and has touched a high and low of Rs. 768.50 and Rs. 754.00 respectively. So far 1638 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1025.00 on 11-Jun-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharmaceuticals trades higher on getting final nod from USFDA for Pirfenidone Tablets
Alembic Pharmaceuticals trades higher on getting final nod from USFDA for Pirfenidone Tablets
Source: Accord Fintech
24/05/2022 11:19:07 AM
Alembic Pharmaceuticals trades in green on the bourses Alembic Pharmaceuticals is currently trading at Rs. 730.00, up by 4.90 points or 0.68% from its previous closing of Rs. 725.10 on the BSE. The scrip opened at Rs. 724.90 and has touched a high and low of Rs. 730.00 and Rs. 713.30 respectively. So far 2098 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1025.00 on 11-Jun-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharmaceuticals trades in green on the bourses
Alembic Pharmaceuticals trades in green on the bourses
Source: Accord Fintech
12/05/2022 2:32:04 PM
Alembic Pharmaceuticals spurts on getting USFDA’s final approval for Arformoterol Tartrate Inhalation Solution Alembic Pharmaceuticals is currently trading at Rs. 726.60, up by 6.35 points or 0.88% from its previous closing of Rs. 720.25 on the BSE. The scrip opened at Rs. 720.00 and has touched a high and low of Rs. 732.90 and Rs. 716.05 respectively. So far 27295 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1025.00 on 11-Jun-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip...
Alembic Pharmaceuticals spurts on getting USFDA’s final approval for Arformoterol Tartrate Inhalation Solution
Alembic Pharmaceuticals spurts on getting USFDA’s final approval for Arformoterol Tartrate Inhalation Solution
Source: Accord Fintech
11/05/2022 3:04:19 PM
Buy Alembic Pharmaceuticals Ltd For Target Rs.1,250 - Yes Securities Await US capex monetization Result Synopsis Alembic clocked 11% growth in 4Q, on the back of strong growth in India business which continued its outperformance vs IPM. US business delivered a surprisingly good quarter driven by inventory stocking, one-time sales of few products and market share ramp up in existing business. Company also acquired remaining 40% of Aleor business making it a wholly owned subsidiary; company wrote off Rs1.88bn in Aleor R&D with another Rs1.5bn to be w/o...
Buy Alembic Pharmaceuticals Ltd For Target Rs.1,250 - Yes Securities
Buy Alembic Pharmaceuticals Ltd For Target Rs.1,250 - Yes Securities
Source: Yes Securities Ltd
4/05/2022 11:12:54 AM
Alembic Pharmaceutic Q4 net profit up 8.77% at Rs 251.37 cr The company reported standalone net profit of Rs 251.37 crore for the quarter ended March 31, 2022 as compared to Rs 231.11 crore in the same period last year, registering a year-on-year growth of 8.77 per cent. Net revenue of the company rose moderately by 12.71 per cent at Rs 1,304.32 crore in January-March quarter of this fiscal as against Rs 1,157.24 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 21.14 per cent to Rs 1,013.01 cro...
Alembic Pharmaceutic Q4 net profit up 8.77% at Rs 251.37 cr
Alembic Pharmaceutic Q4 net profit up 8.77% at Rs 251.37 cr
Source: Dion Global Solutions Ltd
3/05/2022 4:55:52 PM
Alembic Pharmaceuticals rises on the bourses Alembic Pharmaceuticals is currently trading at Rs. 784.40, up by 2.65 points or 0.34% from its previous closing of Rs. 781.75 on the BSE. The scrip opened at Rs. 790.00 and has touched a high and low of Rs. 790.00 and Rs. 780.60 respectively. So far 2128 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharmaceuticals rises on the bourses
Alembic Pharmaceuticals rises on the bourses
Source: Accord Fintech
27/04/2022 11:06:27 AM
Alembic Pharmaceuticals shines on getting USFDA’s approval for Ivabradine Tablets Alembic Pharmaceuticals is currently trading at Rs. 764.00, up by 15.20 points or 2.03% from its previous closing of Rs. 748.80 on the BSE. The scrip opened at Rs. 754.00 and has touched a high and low of Rs. 765.20 and Rs. 750.00 respectively. So far 2124 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip...
Alembic Pharmaceuticals shines on getting USFDA’s approval for Ivabradine Tablets
Alembic Pharmaceuticals shines on getting USFDA’s approval for Ivabradine Tablets
Source: Accord Fintech
20/04/2022 11:49:28 AM
Key News - Hero MotoCorp, Coal India ,HDFC Bank, Tata Steel Ltd, L&T Technology Services By ARETE Securities Key News Hero MotoCorp made over Rs 1k-cr bogus expenses, I-T search reveals: Report The Income Tax Department has found that Hero MotoCorp made more than Rs 1,000 crore bogus expenses and over Rs 100- crore cash transactions for a farmhouse in Chhattarpur, Delhi, sources told ANI. Income Tax Department carried out a search and seizure operation on March 23 on Hero Motocorp and its chairman and managing director Pawan Munjal at multiple locations in Delhi-NCR, which concluded on Marc...
Key News - Hero MotoCorp, Coal India ,HDFC Bank, Tata Steel Ltd, L&T Technology Services By ARETE Securities
Key News - Hero MotoCorp, Coal India ,HDFC Bank, Tata Steel Ltd, L&T Technology Services By ARETE Securities
Source: ARETE Securities Ltd
30/03/2022 10:11:13 AM
Alembic Pharmaceuticals gains on getting USFDA’s tentative approval for Macitentan Tablets Alembic Pharmaceuticals is currently trading at Rs. 729.90, up by 0.85 points or 0.12% from its previous closing of Rs. 729.05 on the BSE. The scrip opened at Rs. 730.45 and has touched a high and low of Rs. 737.75 and Rs. 725.00 respectively. So far 5095 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharmaceuticals gains on getting USFDA’s tentative approval for Macitentan Tablets
Alembic Pharmaceuticals gains on getting USFDA’s tentative approval for Macitentan Tablets
Source: Accord Fintech
15/03/2022 3:14:06 PM
Alembic Pharma rises as its JV gets USFDA’s final approval for Nystatin and Triamcinolone Acetonide Ointment Alembic Pharmaceuticals is currently trading at Rs. 713.55, up by 2.80 points or 0.39% from its previous closing of Rs. 710.75 on the BSE. The scrip opened at Rs. 708.60 and has touched a high and low of Rs. 727.85 and Rs. 706.15 respectively. So far 5511 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022. Last one week high and low of the scrip ...
Alembic Pharma rises as its JV gets USFDA’s final approval for Nystatin and Triamcinolone Acetonide Ointment
Alembic Pharma rises as its JV gets USFDA’s final approval for Nystatin and Triamcinolone Acetonide Ointment
Source: Accord Fintech
8/03/2022 2:46:02 PM
Alembic Pharma gains on getting USFDA’s nod for Fesoterodine Fumarate Extended-Release Tablets Alembic Pharmaceuticals is currently trading at Rs. 770.75, up by 8.60 points or 1.13% from its previous closing of Rs. 762.15 on the BSE. The scrip opened at Rs. 762.20 and has touched a high and low of Rs. 772.90 and Rs. 761.75 respectively. So far 1713 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 715.00 on 28-Jan-2022. Last one week high and low of the scrip ...
Alembic Pharma gains on getting USFDA’s nod for Fesoterodine Fumarate Extended-Release Tablets
Alembic Pharma gains on getting USFDA’s nod for Fesoterodine Fumarate Extended-Release Tablets
Source: Accord Fintech
2/02/2022 11:13:54 AM
Quote on Alembic Pharmaceuticals By Mr. Yash Gupta, Angel One Ltd Below is quote on Alembic Pharmaceuticals receives USFDA Tentative Approval for Dronedarone, positive news for alembic pharmaceuticals, stock up 2% by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Alembic Pharmaceuticals announced that the company has received US Food & Drug Administration (USFDA) Tentative Approval for Dronedarone Tablets USP, 400 mg. The tentatively approved ANDA is therapeutically equivalent to ...
Quote on Alembic Pharmaceuticals By Mr. Yash Gupta, Angel One Ltd
Quote on Alembic Pharmaceuticals By Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
10/01/2022 5:16:35 PM
Alembic Pharmaceuticals jumps on getting USFDA’s tentative approval for Dronedarone Tablets USP Alembic Pharmaceuticals is currently trading at Rs. 816.90, up by 10.15 points or 1.26% from its previous closing of Rs. 806.75 on the BSE. The scrip opened at Rs. 809.00 and has touched a high and low of Rs. 820.00 and Rs. 807.85 respectively. So far 8673 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1119.00 on 13-Jan-2021 and a 52 week low of Rs. 720.80 on 23-Aug-2021. Last one week high and low of the scrip...
Alembic Pharmaceuticals jumps on getting USFDA’s tentative approval for Dronedarone Tablets USP
Alembic Pharmaceuticals jumps on getting USFDA’s tentative approval for Dronedarone Tablets USP
Source: Accord Fintech
10/01/2022 12:03:50 PM
Alembic Pharmaceuticals gains on getting USFDA’s final approval for Entacapone tablets Alembic Pharmaceuticals is currently trading at Rs. 823.50, up by 7.30 points or 0.89% from its previous closing of Rs. 816.20 on the BSE. The scrip opened at Rs. 807.00 and has touched a high and low of Rs. 826.90 and Rs. 800.00 respectively. So far 14520 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1119.00 on 13-Jan-2021 and a 52 week low of Rs. 720.80 on 23-Aug-2021. Last one week high and low of the scrip...
Alembic Pharmaceuticals gains on getting USFDA’s final approval for Entacapone tablets
Alembic Pharmaceuticals gains on getting USFDA’s final approval for Entacapone tablets
Source: Accord Fintech
6/01/2022 4:27:28 PM
Key News - State Bank of India Ltd, DHFL, Life Insurance Corporation, Alembic Pharmaceuticals Ltd, Axis Bank Ltd By ARETE Securities Key News India's largest bank SBI to invest $20 mn in fintech firm Pine Labs Pine Labs, a leading merchant commerce platform, announced a new investment of $20 million from India’s largest commercial bank, the State Bank of India (SBI). Earlier in 2021, Pine Labs had raised a total round size of $600 million from a marquee set of new investors and followed it up with a $100 million fundraise from US-based Invesco Developing Markets Fund. In addition to augmenting its merchant...
Key News - State Bank of India Ltd, DHFL, Life Insurance Corporation, Alembic Pharmaceuticals Ltd, Axis Bank Ltd By ARETE Securities
Key News - State Bank of India Ltd, DHFL, Life Insurance Corporation, Alembic Pharmaceuticals Ltd, Axis Bank Ltd By ARETE Securities
Source: ARETE Securities Ltd
5/01/2022 9:35:43 AM
Alembic Pharmaceuticals rises on getting USFDA’s final nod for Doxycycline Hyclate Delayed release tablets Alembic Pharmaceuticals is currently trading at Rs. 812.00, up by 2.40 points or 0.30% from its previous closing of Rs. 809.60 on the BSE. The scrip opened at Rs. 807.00 and has touched a high and low of Rs. 814.00 and Rs. 802.00 respectively. So far 8400 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1119.00 on 13-Jan-2021 and a 52 week low of Rs. 720.80 on 23-Aug-2021. Last one week high and low of the scrip ...
Alembic Pharmaceuticals rises on getting USFDA’s final nod for Doxycycline Hyclate Delayed release tablets
Alembic Pharmaceuticals rises on getting USFDA’s final nod for Doxycycline Hyclate Delayed release tablets
Source: Accord Fintech
4/01/2022 11:15:58 AM
Neutra Alembic Pharma Ltd For Target Rs 860 - Motilal Oswal Weakness in US outweighs strong performance in DF Injectables business traction hinges on successful compliance * Alembic Pharma (ALPM) delivered in-line 2QFY22 earnings. Subdued performance in US/API was offset by a better-than-expected show in the Domestic Formulation (DF) segment. The YoY declining trend in the US business has reached a trough with the limited impact of price erosion and an increased pace of launches going forward. * We lower our FY22E/FY23E EPS estimate by 7...
Neutra Alembic Pharma Ltd For Target Rs 860 - Motilal Oswal
Neutra Alembic Pharma Ltd For Target Rs 860 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
29/12/2021 12:20:20 PM
Hold Alembic Pharmaceuticals Ltd For Target Rs.818 - ICICI Securities India shines; US struggles Alembic Pharma (Alembic) reported Q2FY22 performance was broadly in line with our estimates. Revenue in US was below expectation at ~US$47mn due to continuous pricing pressure mainly in sartans & Theophylline. Revenues declined 11.3% YoY to Rs12.9bn, adjusted profit declined 49.2% YoY to Rs1.7bn and EBITDA margin dropped to 19.9% (-1,050bps YoY and +210bps QoQ). We believe near term outlook remains muted due to significant erosion in US sales which would also...
Hold Alembic Pharmaceuticals Ltd For Target Rs.818 - ICICI Securities
Hold Alembic Pharmaceuticals Ltd For Target Rs.818 - ICICI Securities
Source: ICICI Securities Ltd
17/12/2021 9:56:50 AM
Hold Alembic Pharma Ltd For Target Rs.790 - ICICI Direct US challenges offset domestic performance… About the stock: Alembic Pharma operates in international generics (US:27% & ExUS:15% in H1FY22), domestic branded (37% in H1FY22) and API (20% in H1FY22). * Domestic business has 1.5% of market share of IPM with three brands in the top 100. Going ahead, emphasis is on specialty segment with 94% of new launches being specialty products * The company has invested ~ | 1800 crore in recent years in facilities geared mainly towards US...
Hold Alembic Pharma Ltd For Target Rs.790 - ICICI Direct
Hold Alembic Pharma Ltd For Target Rs.790 - ICICI Direct
Source: ICICI Direct
14/12/2021 10:55:32 AM
Alembic Pharmaceuticals gains on getting EIR from USFDA for Gujarat new injectable facility Alembic Pharmaceuticals is currently trading at Rs. 827.55, up by 8.10 points or 0.99% from its previous closing of Rs. 819.45 on the BSE. The scrip opened at Rs. 831.90 and has touched a high and low of Rs. 863.10 and Rs. 818.55 respectively. So far 75015 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 720.80 on 23-Aug-2021. Last one week high and low of the scrip...
Alembic Pharmaceuticals gains on getting EIR from USFDA for Gujarat new injectable facility
Alembic Pharmaceuticals gains on getting EIR from USFDA for Gujarat new injectable facility
Source: Accord Fintech
12/10/2021 3:28:18 PM
Quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Angel One Ltd Below is quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Alembic Pharmaceuticals receives EIR for its New Injectable Facility from USFDA. Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its New Injectable Facility (F-3) at Karakhadi from USFDA ( US Food & Drug Administration). USFDA has done an inspection at new&...
Quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Angel One Ltd
Quote on Alembic Pharmaceuticals receive EIR from USFDA by Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
11/10/2021 5:35:55 PM
Buy Alembic Pharmaceuticals Ltd Target Rs.815 - Religare Broking Religare Super Idea   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330   Above views are of the author and not of the website kindly read disclaimer
Buy Alembic Pharmaceuticals Ltd Target Rs.815 - Religare Broking
Buy Alembic Pharmaceuticals Ltd Target Rs.815 - Religare Broking
Source: Religare Broking Ltd
3/09/2021 10:44:39 AM
Buy Alembic Pharma Ltd For Target Rs.1,200 - Monarch Networth Capital Key MeetingTakeaways US business: * Pivoting from supply-focused to volume-focused strategy i.e. getting more market share with focus on cost optimization. Expects hit on medium-term perspective on account of the same. * Supply disruptions coupled with increased competition is leading to the inability to take price increases in the US markets. There is pressure in the base portfolio. However, Q1FY22 looks like the bottom in terms of margins.   Domestic business: * Acute...
Buy Alembic Pharma Ltd For Target Rs.1,200 - Monarch Networth Capital
Buy Alembic Pharma Ltd For Target Rs.1,200 - Monarch Networth Capital
Source: Monarch Networth Capital Ltd
20/08/2021 11:45:11 AM
Hold Alembic Pharma Ltd For Target Rs. 885 - ICICI Direct US challenges offset domestic recovery… About the stock: Alembic Pharma operates in international generics (54%), domestic branded (28%) and API (18%). * Exports contribute 69% of sales (US~74%), domestic contributes 31% of sales (Chronic~69% & Acute~31%) * It has filed 212 ANDA and has 146 approvals with 94 product launches   Q1FY22 Results: Alembic reported skewed Q1FY22 results. * Sales declined 1.1% YoY to | 1326 crore * EBITDA in Q1FY22 was at ...
Hold Alembic Pharma Ltd For Target Rs. 885 - ICICI Direct
Hold Alembic Pharma Ltd For Target Rs. 885 - ICICI Direct
Source: ICICI Direct
9/08/2021 12:56:42 PM
Buy Alembic Pharmaceuticals Ltd Ltd For Target Rs. 1,200 - Monarch Networth INVESTMENT THESIS Alembic Pharmaceuticals Ltd (‘ALPM’) reported a weaker than expected Q1FY22 performance on the back of headwinds in key products (Sartans and Theophylline) and pricing pressure in the base portfolio. India business reported an excellent set growing by 57% on the back of Azithromycin in Acute portfolio. Subdued US performance was on the back of headwinds coming from Theophylline competition and pricing erosion in the base portfolio, which is likely to continue ...
Buy Alembic Pharmaceuticals Ltd Ltd For Target Rs. 1,200 - Monarch Networth
Buy Alembic Pharmaceuticals Ltd Ltd For Target Rs. 1,200 - Monarch Networth
Source: Monarch Networth
28/07/2021 2:18:10 PM